In a patient with chronic heart failure and chronic obstructive pulmonary disease, which beta‑blocker is preferred: carvedilol (Coreg) or metoprolol?

Beta-Blocker Selection in Heart Failure with COPD

In patients with chronic heart failure and COPD, beta-1 selective beta-blockers (bisoprolol or metoprolol succinate) are preferred over the non-selective beta-blocker carvedilol due to better pulmonary tolerability, though all three evidence-based beta-blockers reduce mortality in heart failure and COPD is not a contraindication to any of them.

Guideline-Recommended Beta-Blockers

Only three beta-blockers have proven mortality reduction in heart failure and should be used 1, 2, 3:

• Bisoprolol (beta-1 selective)
• Metoprolol succinate/CR/XL (beta-1 selective)
• Carvedilol (non-selective beta-blocker with alpha-1 blocking activity)

The benefits of beta-blockers cannot be assumed to be a class effect—other beta-blockers should not be used 1.

COPD-Specific Considerations

COPD is NOT a contraindication to beta-blocker therapy 4, 5, 4. The majority of patients with heart failure and COPD can safely tolerate beta-blocker therapy 4. However:

• Asthma remains an absolute contraindication to any beta-blocker 4, 6
• Active bronchospasm is a contraindication 5
• Beta-1 selective agents are preferred when pulmonary disease is present 5

Evidence for Beta-1 Selective vs Non-Selective Beta-Blockers

Pulmonary Effects

Beta-1 selective agents cause less airway compromise in COPD patients:

• In a randomized crossover trial, carvedilol caused significantly lower FEV1 compared to bisoprolol in COPD patients (carvedilol 1.85 L/s vs bisoprolol 2.0 L/s, p<0.001) 7
• The same study found carvedilol caused the most airway function deterioration, while bisoprolol caused the least 7
• Carvedilol was poorly tolerated in asthma patients (only 50% tolerated it) but better tolerated in COPD (84% tolerated it) 6

Heart Failure Outcomes

Multiple studies show carvedilol users have worse heart failure outcomes in the COPD population:

• Carvedilol users had 61% higher hazard of heart failure hospitalization compared to metoprolol/bisoprolol/nebivolol users (adjusted HR 1.61,95% CI 1.52-1.70) 8
• In geriatric patients with heart failure, COPD, and diabetes, carvedilol users had 38% higher hazard of heart failure hospitalization than metoprolol users (HR 1.38,95% CI 1.19-1.60) 9
• Bisoprolol showed dose-response survival benefit in heart failure patients with COPD, while carvedilol and metoprolol showed no survival difference 10

Persistence and Tolerability

Carvedilol users had significantly lower treatment persistence time than metoprolol/bisoprolol/nebivolol users in the COPD population 8.

Practical Prescribing Algorithm

Start with beta-1 selective agents in heart failure patients with COPD:

1. First choice: Bisoprolol or Metoprolol succinate

   • Bisoprolol: Start 1.25 mg once daily, target 10 mg once daily 1
   • Metoprolol CR/XL: Start 12.5-25 mg once daily, target 200 mg once daily 1

2. Initiation strategy:

   • Start at low dose with gradual up-titration 4
   • Double dose every 2 weeks if tolerated 1
   • Mild deterioration in pulmonary function should not lead to prompt discontinuation 4

3. Monitoring:

   • Watch for worsening dyspnea, wheezing, or bronchospasm
   • Monitor heart rate, blood pressure, and clinical status 1
   • Inhaled beta-agonists should be administered as required 4

Common Pitfalls to Avoid

• Do not withhold beta-blockers entirely in COPD patients with heart failure—the mortality benefit is substantial and COPD is not a contraindication 4
• Do not use carvedilol as first-line in patients with moderate-to-severe COPD due to increased airway effects and worse heart failure outcomes 7, 8, 9
• Do not confuse COPD with asthma—asthma is an absolute contraindication to all beta-blockers, while COPD is not 4, 6
• Do not stop beta-blockers for mild pulmonary symptoms—gradual titration and reassurance usually allow continuation 4

When Carvedilol Might Be Considered

Carvedilol may be preferentially chosen in patients with concurrent chronic kidney disease, atrioventricular block, or cerebrovascular disease based on observational data 11, though this does not override the pulmonary and heart failure hospitalization concerns in COPD patients.